Highest-materiality recent filing
Zivo Bioscience to voluntarily deregister, cease SEC reporting; CFO and director resign
CFO William Sullivan resigns effective March 30, 2026; board member Alison Cornell resigns immediately as part of cost-cutting measures.
CFO Keith Marchiando resigns; William Sullivan appointed Interim CFO
Keith Marchiando resigns as CFO effective Dec 31, 2025; receives $27,040/mo through Dec 31, 2026.
Zivo Bioscience raises $250k initial tranche in $2M convertible debt offering
Issued $250k bridge promissory note with 10% annual interest, compounded annually; due after 2 years or upon $5M+ equity financing.
Zivo Bioscience issues 191,698 shares, raises ~$1.5M from accredited investor since Nov 2024
Sold 75,000 shares at $20.19 each to one accredited investor, gross proceeds ~$1.5M.
Adopted 2024 Director Equity Plan (875k shares, auto-increase 5%/yr). Director cash fee raised from $40k to $50k, eligible for restricted stock/RSUs.
On July 11, 2024, the Board of Directors of ZIVO Bioscience Inc., (the “Company”) increased its size from four (4) to five (5) members and appointed Laith Yaldoo to fill the vacancy.
Max materiality 0.80 · Median 0.50 · Most common event other_material